Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Pfizer Inc ., of New York, reported top-line results from two Phase III trials of tofacitinib, an oral Janus kinase (JAK) inhibitor being investigated to treat adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OP ...

BioWorld Today - Staff - 2013-10-09 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, disclosed results of a Phase I/II study of its intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adult volunteers who were challenged with the most commonly occurring noroviru ...

BioWorld Today - Staff - 2013-10-06 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Abbvie Inc. , of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate ...

BioWorld Today - Staff - 2013-10-03 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• D&A Pharma , of Paris, will participate in the 14th Congress of the European Society for Biomedical Research on Alcoholism (ESBRA) in Warsaw Sept. 8-11, with results of trials of Alcover (sodium oxybate) showing that the drug met therapeutic ...

BioWorld Today - Staff - 2013-09-08 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Eli Lilly and Co. , of Indianapolis, disclosed positive patient-reported health outcomes from a Phase III trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a once-weekly treatment for ...

BioWorld Today - Staff - 2013-09-26 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Research and Development LLC , of Raritan, N.J., a unit of Johnson & Johnson, said results from a 52-week analysis of a Phase III trial of Invokana (canagliflozin) showed substantial improvements in glycemic control for patients with Ty ...

BioWorld Today - Staff - 2013-09-24 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Pharmaceuticals Inc. , of Raritan, N.J., part of Johnson & Johnson, said a pooled analysis of the Phase III EINSTEIN program showed Xarelto (rivaroxaban) is as effective as standard of care in reducing the risk of deep vein thrombosis ( ...

BioWorld Today - Staff - 2013-09-22 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Ipsen SA , of Paris, reported positive top-line findings from the primary endpoint of the ELECT study assessing the effect of Somatuline Autogel/Somatuline Depot (lanreotide) Injection 120 mg in controlling symptoms in patients with neuroendocrine ...

BioWorld Today - Staff - 2013-09-17 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Forest Laboratories Inc ., of New York, received Qualified Infectious Disease Product designation from the FDA for ceftazidime/avibactam. (BioWorld-Today-2013-09-16) ...

BioWorld Today - Staff - 2013-09-15 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported Phase III data at the European Respiratory Society meeting in Barcelona, Spain, showing that once-daily olodaterol Respimat maintained lung function improvements in addition to usual c ...

BioWorld Today - Staff - 2013-09-09 23:00 - 0 comments - 0 attachments